AI Science Tracker

University of California, Los Angeles

1 discovery from 2023

Discoveries

Deep learning detects elevated tissue-derived cfDNA across cancer and cirrhosis cohorts

A study built a fragment-level methylation atlas from 521 noncancer tissue samples spanning 29 human tissue types and used it with cfSort, a supervised deep neural network, to estimate tissue composition in plasma cell-free DNA. Applying cfSort to patient data, the investigators found higher cfDNA fractions from the affected tissue in liver, lung, colorectal and stomach cancer and cirrhosis cohorts than in healthy controls; the estimated fractions also increased with cancer stage. The tissue-origin signal was reproduced on an independent whole-genome-bisulfite-sequencing dataset for liver cancer. In serial samples from four non-small-cell lung cancer patients receiving anti-PD-1 therapy, estimated liver or kidney tissue fractions tracked measured biochemical markers of organ injury.

Technology: cfSort, an ensemble of two dense deep neural networks trained on simulated mixtures using a fragment-level tissue methylation atlas

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Applying cfSort to patient data, the investigators found higher cfDNA fractions from the affected tissue in liver, lung, colorectal and stomach cancer and cirrhosis cohorts than in healthy controls; the estimated fractions also increased with cancer stage.
  • Still unknown: The disease cohorts were retrospective and the clinical analyses demonstrate association and measurement feasibility, not prospective diagnostic benefit or improved outcomes. The clinical groups were 21 cirrhosis patients and 201 cancer patients, with 100 healthy controls; cross-platform liver-cancer validation used 24 cases and 32 controls. Anti-PD-1 injury monitoring involved only four NSCLC patients at three timepoints. The authors note that disease-specific methylation markers could improve cancer detection beyond tissue-of-origin fractions.
  • AI role: The team used the supervised cfSort model to deconvolve methylation profiles in plasma cfDNA and estimate contributions from 29 tissue types. This enabled the reported comparison of affected-tissue cfDNA fractions in cancer and cirrhosis patient cohorts versus controls and longitudinal tracking of tissue-injury signals during immunotherapy. The atlas and model were also evaluated against simulated mixtures and independent methylation data.

Evidence sources: https://par.nsf.gov/servlets/purl/10428542

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 77 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.